SymBio Pharmaceuticals Limited (SYMQY)

OTCMKTS · Delayed Price · Currency is USD

0.5579

0.00 (0.00%)

Aug 10, 2026, 4:00 PM EST

-55.37% (1Y)

Market Cap	31.78M -38.3%
Revenue (ttm)	6.95M -37.7%
Net Income	-37.07M
EPS	-0.60
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Open	0.5579
Previous Close	0.5579
Day's Range	0.5579 - 0.6603
52-Week Range	0.5579 - 1.3100
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2005

Employees 91

Stock Exchange OTCMKTS

Ticker Symbol SYMQY

Financial Performance

In 2025, SymBio Pharmaceuticals's revenue was 1.31 billion, a decrease of -46.70% compared to the previous year's 2.45 billion. Losses were -4.78 billion, 24.6% more than in 2024.

Financial numbers in JPY Financial Statements